Want to see PHGE full AI Analyst Report?
Top Page
BiomX
(PHGE)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.18
▼(-4.74% Downside)
Action:Reiterated
Date:07/25/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn with negative equity) and a clearly bearish technical setup (price far below key moving averages with negative MACD). Corporate events provide some support via a clearer defense-focused strategy and a listing compliance extension, but dilution and compliance risks, along with limited valuation support due to negative earnings, keep the overall score low.
Positive Factors
Strategic Repositioning to Defense
Management executed a lasting business-model shift from clinical biotech to an acquisition-led defense and security holding company. This creates clearer commercial pathways (contracts, product sales) versus trial-dependent revenue, aligning resources toward recurring defense procurement and platform aggregation.
Negative Factors
No Revenue, Persistent Losses
The company currently lacks an ongoing revenue base and reports consistent operating losses and negative gross profit. Even after the strategic pivot, absence of established recurring sales means continued reliance on financing; sustained losses increase dilution and constrain reinvestment ability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Repositioning to Defense
Management executed a lasting business-model shift from clinical biotech to an acquisition-led defense and security holding company. This creates clearer commercial pathways (contracts, product sales) versus trial-dependent revenue, aligning resources toward recurring defense procurement and platform aggregation.
Read all positive factors
BiomX (PHGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.17M
Dividend YieldN/A
Average Volume (3M)1.32M
Price to Earnings (P/E)―
Beta (1Y)-0.04
Revenue GrowthN/A
EPS Growth-92.20%
CountryUS
Employees20
SectorIndustrials
Sector Strength72
IndustryAerospace & Defense
Share Statistics
EPS (TTM)-23.30
Shares Outstanding11,797,449
10 Day Avg. Volume1,108,900
30 Day Avg. Volume1,322,820
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-100.26
Price to Sales (P/S)0.00
P/FCF Ratio-4.95
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.85
Revenue Forecast (FY)N/A
BiomX Business Overview & Revenue Model
Company Description
Operating as a holding company, BiomX Inc. is dedicated to advancing technologies within the realms of defense, security, and essential infrastructure. Its diverse array of offerings features specialized solutions like counter-unmanned aerial vehi...
How the Company Makes Money
BiomX is a clinical-stage company and, as such, it generally does not rely on recurring product sales; instead, its ability to generate revenue is primarily tied to funding and collaboration-based sources. Key ways the company may generate revenue...
BiomX Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and positive regulatory feedback which provides a strong outlook for future developments. However, financial challenges and regulatory holds present ongoing risks. Optimism in phage therapy's future and strategic plans for BX011 and BX004 suggest a cautiously positive sentiment.Positive Updates
BX004 Phase IIb Trial Progress and FDA Feedback
The BX004 program for cystic fibrosis patients showed significant progress with first patient dosing in the Phase IIb trial. Despite a clinical hold on U.S. trial sites due to a third-party nebulizer device, the European trial continues uninterrupted. FDA feedback recognized the unmet need for treatments targeting chronic Pseudomonas aeruginosa infections and provided constructive guidance for development pathways, including Phase III criteria.
Negative Updates
Clinical Hold on BX004 U.S. Trial Sites
The FDA placed a clinical hold on BX004 U.S. trial sites due to concerns with a third-party nebulizer device, not the drug candidate itself. This temporary pause affects U.S. sites while awaiting further FDA feedback, although European enrollment continues as planned.
Read all updates
Q3-2025 Updates
Positive
Negative
BX004 Phase IIb Trial Progress and FDA Feedback
The BX004 program for cystic fibrosis patients showed significant progress with first patient dosing in the Phase IIb trial. Despite a clinical hold on U.S. trial sites due to a third-party nebulizer device, the European trial continues uninterrupted. FDA feedback recognized the unmet need for treatments targeting chronic Pseudomonas aeruginosa infections and provided constructive guidance for development pathways, including Phase III criteria.
Read all positive updates
Company Guidance
During the BiomX Third Quarter 2025 Financial Results and Program Update Conference Call, the company provided guidance on several metrics. BiomX reported a cash balance of $8.1 million as of September 30, 2025, with expectations that this would fund operations into the first quarter of 2026. Research and development expenses decreased to $6.1 million from $7.3 million in the same quarter of 2024, largely due to workforce reductions and lower rent expenses. The company also noted a net loss of $9.2 million for the quarter, compared to a net income of $9.6 million the previous year, primarily due to changes in the fair value of warrants from its March 2024 financing. Additionally, BiomX is advancing its lead programs, BX004 and BX011, with regulatory engagement and clinical trial progress, despite a temporary FDA clinical hold on BX004 due to a third-party nebulizer device. They expect to report BX004 Phase IIb data in Q1 2026 and have received positive FDA feedback for BX011's development pathway.BiomX Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.69M | -2.92M | -1.80M | -871.00K | 0.00 | 0.00 |
| EBITDA | -26.16M | -32.29M | -13.13M | -22.82M | -23.66M | -32.90M |
| Net Income | -47.68M | -36.20M | -17.73M | -26.17M | -28.32M | -36.23M |
Balance Sheet | ||||||
| Total Assets | 3.25M | 70.24M | 43.23M | 25.03M | 45.53M | 77.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.17M | 4.96M | 17.81M | 14.91M | 33.33M | 62.10M |
| Total Debt | 0.00 | 1.44M | 9.58M | 15.09M | 19.36M | 20.02M |
| Total Liabilities | 4.13M | 71.54M | 19.09M | 21.95M | 24.49M | 30.45M |
| Stockholders Equity | -881.00K | -1.30M | 24.15M | 3.08M | 21.04M | 47.53M |
Cash Flow | ||||||
| Free Cash Flow | -23.09M | -26.39M | -37.01M | -21.34M | -29.20M | -31.25M |
| Operating Cash Flow | -23.09M | -26.39M | -36.98M | -21.29M | -29.09M | -27.57M |
| Investing Cash Flow | -939.00K | 108.00K | 715.00K | 1.95M | -2.11M | 16.17M |
| Financing Cash Flow | 3.90M | 13.19M | 38.37M | 2.90M | 292.00K | 37.28M |
BiomX Technical Analysis
Negative
0.19
Price Trends
0.52
Negative
1.60
Negative
3.50
Negative
Market Momentum
-0.09
Negative
27.42
Positive
34.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.52, and below the 200-day MA of 3.50, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 27.42 is Positive, neither overbought nor oversold. The STOCH value of 34.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHGE.
BiomX Risk Analysis
BiomX disclosed 60 risk factors in its most recent earnings report. BiomX reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BiomX Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
44 Neutral | $17.48M | -1.08 | -66.69% | ― | -45.52% | -94.82% | |
44 Neutral | $8.17M | -1.93 | -43.95% | ― | 11.90% | 43.46% | |
42 Neutral | $2.17M | >-0.01 | -694.46% | ― | ― | -92.20% | |
39 Underperform | $7.22M | -0.73 | -201.06% | ― | ― | ― |
* Industrials Sector Average
PHGE
BiomX
0.19
-8.02
-97.73%
CANF
Can-Fite BioPharma
3.17
-10.32
-76.50%
LPCN
Lipocine
2.11
-1.02
-32.59%
IMRN
Immuron
1.06
-0.62
-36.90%
OSRH
OSR Holdings
0.45
-0.21
-31.91%
BiomX Corporate Events
M&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
BiomX Amends Promissory Note, Issues Restricted Shares
Neutral
Jul 28, 2026
On April 10, 2026, BiomX Inc. completed the acquisition of ZorroNet Ltd., issuing a $1,250,000 promissory note to former owner Water IO Ltd. as part of the consideration. On July 27, 2026, BiomX amended the note to extend its maturity from July 10...
M&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
BiomX Cancels Conversion Shares to Restore NYSE Compliance
Neutral
Jul 10, 2026
On April 13, 2026, BiomX Inc. completed the acquisition of a 60% stake in Dr. Frucht Systems Ltd. from Mandragola Ltd., alongside a revolving credit line of up to $2 million, which later led to the June 2, 2026 issuance of 1,013,637 restricted sha...
Executive/Board ChangesShareholder Meetings
BiomX Shareholders Approve Director, Expand Equity Incentive Plan
Positive
Jun 26, 2026
BiomX Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026, in a virtual format, with 4,518,349 shares represented, or about 40.5% of eligible shares, constituting a quorum for voting. Stockholders elected Ran Shaked as the sole Clas...
Business Operations and StrategyRegulatory Filings and Compliance
BiomX Unveils Strategy as Defense Technology Holding Company
Positive
Jun 18, 2026
On June 18, 2026, BiomX Inc. announced that it had posted an updated informational presentation to its website, reflecting the completion of its strategic transition into a defense and security technology holding company. The presentation, which w...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BiomX Wins NYSE Compliance Plan Extension to 2027
Negative
Jun 12, 2026
BiomX said that on June 10, 2026, NYSE Regulation accepted its plan to regain compliance with NYSE American’s continued listing standards, granting the company until September 25, 2027 to restore required stockholders’ equity levels. T...
M&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
BiomX Issues Restricted Shares Under Mandragola Credit Facility
Neutral
Jun 5, 2026
On June 2, 2026, BiomX Inc. issued 1,013,637 restricted common shares to three assignees upon partial conversion of a Mandragola Ltd. convertible promissory note, reflecting about $379,000 in principal, and bringing total shares outstanding to 11,...
Business Operations and StrategyExecutive/Board Changes
BiomX Appoints Roy Rousso as Chief Business Officer
Positive
May 28, 2026
On May 27, 2026, BiomX Inc. announced that its board appointed Colonel (res.) Roy Rousso as Chief Business Officer, effective July 1, 2026, bringing more than 20 years of leadership experience in digital infrastructure, sovereign cloud, private ce...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
BiomX Reinvents Itself as Diversified Defense Technology Platform
Negative
May 5, 2026
In the first quarter of 2026, BiomX completed a fundamental strategic overhaul, halting all clinical trials, winding down its U.S. phage unit and exiting its legacy biotech operations after its former core subsidiary, BiomX Ltd., entered insolvenc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.